Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.69 |
| ▸ | JAK2 | O60674 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | JAK3 | P52333 | 4/20 | 0.60 |
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | TEC | P42680 | 1/20 | 0.57 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.53 |
| ▸ | TTK | P33981 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018942 | 0.93 | PTK2 (0.61) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL18018793 | 0.88 | EGFR (0.76) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL18018878 | 0.85 | EGFR (0.79) | JAK2EGFRJAK3BTKJAK1 | |
| SCHEMBL4383739 | 0.82 | JAK2 (0.60) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL18018945 | 0.81 | MAP3K7 (0.78) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL3024528 | 0.80 | JAK2 (0.65) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL18018787 | 0.80 | MAP3K7 (0.77) | JAK2EGFRJAK3BTKJAK1 | |
| SCHEMBL22985858 | 0.77 | PTK2 (0.59) | BRD4JAK2EGFRJAK3BTK | |
| SCHEMBL18018944 | 0.77 | SRC (0.69) | JAK2EGFRJAK3BTKJAK1 | |
| SCHEMBL22985888 | 0.77 | JAK3 (0.73) | EGFRJAK3BTKPTK2MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | BRD4 2931/4885JAK2 1800/4885EGFR 2819/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | BRD4 2931/4885JAK2 1800/4885EGFR 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.